Table 2.

Efficacy results in adjuvant-induced arthritis

	Dose p.o.	Paw swelling		Radiology score	Splenomegaly	Thymus involution	Body weight change index	α2M
Compound	mg·kg−1	R % Inhibition	L % Inhibition	R % Inhibition	% inhibition	% inhibition		% inhibition
Teriflunomide	10 qd	86 ± 2ast;**	47 ± 4ast;**	ND	81 ± 4ast;**	ND	-0.1 ± 0.09	ND
	3 qd	61 ± 3ast;**	28 ± 2ast;**	52 ± 8ast;*	64 ± 4ast;**	−32 ± 11	0 ± 0.06	63 ± 10ast;*
	1 qd	45 ± 9ast;	18 ± 10	ND	ND	ND	0.21 ± 0.1	ND
AL8697	30 qd	76 ± 3ast;**	52 ± 3ast;**	ND	73 ± 5ast;**	72 ± 8ast;**	0.49 ± 0.07ast;**	ND
	10 qd	78 ± 2ast;**	49 ± 2ast;**	76 ± 4ast;**	74 ± 3ast;**	46 ± 12ast;	0.57 ± 0.06ast;**	95 ± 2ast;**
	3 qd	67 ± 4ast;**	41 ± 3ast;**	77 ± 6ast;**	74 ± 3ast;**	ND	0.31 ± 0.09ast;	87 ± 3ast;**
	1 qd	59 ± 5ast;**	36 ± 3ast;**	20 ± 27	46 ± 10ast;**	ND	0.14 ± 0.18	34 ± 28
Tofacitinib	20 qd	83 ± 2ast;**	34 ± 3ast;**	94 ± 4ast;**	86 ± 4ast;**	ND	0.38 ± 0.10ast;	72 ± 3 ast;**
	10 qd	79 ± 2ast;**	34 ± 2ast;**	92 ± 3ast;**	77 ± 3ast;**	8 ± 14	0.43 ± 0.07ast;**	83 ± 5ast;**
	3 qd	51 ± 13ast;*	17 ± 7ast;	ND	25 ± 14	ND	0.19 ± 0.13	ND
	10 bid	91 ± 1 ast;**	48 ± 4 ast;**	95 ± 6 ast;**	98 ± 4 ast;**	ND	1.08 ± 0.15ast;**	96 ± 2 ast;**
	3 bid	84 ± 3 ast;**	44 ± 3 ast;**	ND	86 ± 4 ast;**	ND	0.44 ± 0.14ast;	90 ± 2 ast;**
	1 bid	75 ± 7 ast;**	31 ± 4 ast;**	ND	66 ± 7 ast;**	ND	0.18 ± 0.15	57 ± 17 ast;

Data shown are means ± SEM. ***P < 0.001; **P < 0.01;*P < 0.05; significant inhibition, one-way anova.

ND, not determined; R, right hind paw; L, left hind paw.